Status:
COMPLETED
Glioblastoma Response Prediction to Apatinib
Lead Sponsor:
Beijing Sanbo Brain Hospital
Conditions:
Glioblastoma
Eligibility:
All Genders
18-70 years
Brief Summary
Anti-angiogenic therapy is an important treatment strategy for recurrent glioblastoma. Our previous study provided evidence for a potential benefit of apatinib, a humanized monoclonal antibody against...
Eligibility Criteria
Inclusion
- Age 18-70 years old
- recurrent glioblastoma
- received apatinib plus temozolomide treatment，response and survival data were available
- tumor tissues were acquired
Exclusion
- \-
Key Trial Info
Start Date :
April 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04814329
Start Date
April 22 2021
End Date
June 30 2023
Last Update
July 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Capital Medical University Sanbo Brain Hospital
Beijing, China